PRCT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
PRCT is not a strong buy right now for a beginner long-term investor, but it is a reasonable hold/watchlist name. The stock has some positive elements, including insider buying, constructive options positioning, and a recent analyst target increase after a top-line beat. However, the broader analyst trend remains mixed-to-cautious, hedge funds are selling heavily, and the technical setup is only neutral. With no recent major catalyst and no financial snapshot available for the latest quarter, this is not a clear immediate buy for someone who wants to act now without waiting for a better entry.
PRCT is trading pre-market at 26.29, slightly below the reported current price of 26.38 and just above pivot support at 26.003. MACD histogram is positive at 0.319, which supports mild bullish momentum, but it is contracting, so upside strength is not accelerating. RSI_6 at 55.344 is neutral, and moving averages are converging, indicating a range-bound and indecisive trend rather than a strong uptrend. Nearby resistance sits at 28.272 (R1) and 29.674 (R2), while downside support is at 23.734 (S1). Overall, the chart suggests stabilization more than breakout momentum.
["Piper Sandler raised its price target to $35 from $28 and kept Overweight after Q1 results beat on the top line.", "Management reiterated full-year guidance across key metrics.", "Strong domestic capital placements and all-time high ASPs were highlighted in the latest analyst commentary.", "Insiders are buying, with insider buying up 1235.17% over the last month.", "Options data leans mildly bullish with put-call ratios below 1.0."]
["Hedge funds are selling aggressively, with selling up 465.92% over the last quarter.", "Analyst sentiment is mixed, with Baird and others holding Neutral or even bearish views despite recent updates.", "Earlier Q4 results were disappointing and guidance had been cut, which still weighs on sentiment.", "No news was reported in the recent week, so there is no fresh event-driven catalyst.", "The technical setup is neutral rather than strongly trending."]
Latest quarter season: Q1. The latest quarter was described positively by analysts as a top-line beat, and management reiterated full-year guidance across key metrics. The commentary also highlighted strong domestic capital placements and record ASPs, which suggests improving commercial execution. However, the provided financial snapshot is unavailable, so a deeper read on profitability, margins, and cash flow cannot be confirmed from the data here.
Analyst trend is mixed but improving at the margin. Piper Sandler recently raised its target to $35 and stayed Overweight after a strong Q1 update, which is the most positive recent call. Truist and TD Cowen remain Buy-rated but cut targets, while Baird is Neutral and BofA is bearish with an Underperform rating. Wall Street’s pro view is that PRCT has a compelling technology and long-term adoption opportunity; the con view is that execution, market penetration, and profitability remain under pressure. Overall, the analyst crowd is not uniformly bullish, but the latest earnings beat has improved sentiment somewhat.
